Merck KGaA a leading science and technology company and leader in genome editing, collaborated with Washington University in St. Louis, Missouri, USA, for leading towards the optimization of nutritional supplements to restore a healthy gut microbial community (microbiome). This gut bacteria research would use Merck’s genome-editing technology and may lead to diagnostics, and treatment for malnourished children.
Metabiomics Corp., an early-stage molecular diagnostics company entered into a joint venture with Prescient Medicine Holdings, LLC, a company that operates in the Medical Devices industry to develop an innovative microbiome diagnostics platform. This platform will detect precancerous colon polyps and diagnose other types of gastrointestinal diseases including Crohn’s, colitis (IBD), and irritable bowel syndrome (IBS).
Author Credits: Radhika Gupta, Shivam Bhutani